key: cord-0272994-g8umcy8j
authors: Miura, F.; Leung, K. Y.; Klinkenberg, D.; Ainslie, K. E. C.; Wallinga, J.
title: Optimal vaccine allocation for COVID-19 in the Netherlands: a data-driven prioritization
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.20.21260889
sha: aab9e4604fecbd00b3d773fc23673e2ab2e490b8
doc_id: 272994
cord_uid: g8umcy8j

For the control of COVID-19, vaccination programmes provide a long-term solution. The amount of available vaccines is often limited, and thus it is crucial to determine the allocation strategy. While mathematical modelling approaches have been used to find an optimal distribution of vaccines, there is an excessively large number of possible schemes to be simulated. Here, we propose an algorithm to find a near-optimal allocation scheme given an intervention objective such as minimization of new infections, hospitalizations, or deaths, where multiple vaccines are available. The proposed principle for allocating vaccines is to target subgroups with the largest reduction in the outcome of interest, such as new infections, due to vaccination that fully immunizes a single individual. We express the expected impact of vaccinating each subgroup in terms of the observed incidence of infection and force of infection. The proposed approach is firstly evaluated with a simulated epidemic and then applied to the epidemiological data on COVID-19 in the Netherlands. Our results reveal how the optimal allocation depends on the objective of infection control. In the case of COVID-19, if we wish to minimize deaths, the optimal allocation strategy is not efficient for minimizing other outcomes, such as infections. In simulated epidemics, an allocation strategy optimized for an outcome outperforms other strategies such as the allocation from young to old, from old to young, and at random. Our simulations clarify that the current policy in the Netherlands (i.e., allocation from old to young) was concordant with the allocation scheme that minimizes deaths. The proposed method provides an optimal allocation scheme, given routine surveillance data that reflect ongoing transmissions. The principle of allocation is useful for providing plausible simulation scenarios for complex models, which give a more robust basis to determine intervention strategies.

For the control of COVID-19, vaccination programmes provide a long-term solution. The 47 amount of available vaccines is often limited, and thus it is crucial to determine the allocation 48 strategy. While mathematical modelling approaches have been used to find an optimal 49 distribution of vaccines, there is an excessively large number of possible schemes to be simulated. 50

Here, we propose an algorithm to find a near-optimal allocation scheme given an 51

intervention objective such as minimization of new infections, hospitalizations, or deaths, where 52 multiple vaccines are available. The proposed principle for allocating vaccines is to target 53 subgroups with the largest reduction in the outcome of interest, such as new infections, due to 54 vaccination that fully immunizes a single individual. We express the expected impact of 55 vaccinating each subgroup in terms of the observed incidence of infection and force of infection. 56

The proposed approach is firstly evaluated with a simulated epidemic and then applied to the 57 epidemiological data on COVID-19 in the Netherlands. 58

Our results reveal how the optimal allocation depends on the objective of infection control. 59

In the case of COVID-19, if we wish to minimize deaths, the optimal allocation strategy is not 60 efficient for minimizing other outcomes, such as infections. In simulated epidemics, an allocation 61 strategy optimized for an outcome outperforms other strategies such as the allocation from young 62 to old, from old to young, and at random. Our simulations clarify that the current policy in the 63

Netherlands (i.e., allocation from old to young) was concordant with the allocation scheme that 64 minimizes deaths. 65

The proposed method provides an optimal allocation scheme, given routine surveillance 66 data that reflect ongoing transmissions. The principle of allocation is useful for providing plausible 67

simulation scenarios for complex models, which give a more robust basis to determine 68 intervention strategies.

Author summary 72 Vaccination is the key to controlling the ongoing COVID-19 pandemic. In the early stages of 73 an epidemic, there is shortage of vaccine stocks. Here, we propose an algorithm that computes an 74 optimal vaccine distribution among groups for each intervention objective (e.g., minimizing new 75 infections, hospitalizations, or deaths). Unlike existing approaches that use detailed information on 76

at-risk contacts between and among groups, the proposed algorithm requires only routine 77 surveillance data on the number of cases. This method is applicable even when multiple vaccines 78 are available. Simulation results show that the allocation scheme optimized by our algorithm 79

performed the best compared with other strategies such as allocating vaccines at random and in 80 the order of age. Our results also reveal that an allocation scheme optimized for one specific 81 objective is not necessarily efficient for another, indicating the importance of the decision-making 82 at the early phase of distributions. 83 84 Introduction 85 SARS-CoV-2 has posed a great threat to public health. As of 8 July 2021, 33,270,049 cases 86 and 740,809 deaths with COVID-19 have been reported in the EU/EEA (1), and globally there have 87 been 4,006,882 deaths reported (2). While non-pharmaceutical interventions (NPIs) reduce 88

transmission (3, 4) , the societal cost of implementing these measures is enormous (5,6), and the 89 effect is short-lived. Vaccination offers a long-term approach to control Currently, sixteen vaccines have been approved for use, 99 companies are still conducting 91 clinical trials to develop next generation vaccines (7). There is a limited amount of vaccine 92 available, especially in low-and middle-income countries, because of narrow production capacity 93 and logistics (2, 8, 9) . There is an urgent need to optimize the allocation of scarce vaccines. 94

The optimal allocation depends on the objective of infection control. If the objective is to 95 minimize hospitalizations, it might be best to target those with the highest risk of severe illness 96 upon infection. If the objective is to reduce transmission of infection, it might be best to target the 97 individuals who contribute most to future infections. Similar allocation problems were previously 98 explored for influenza vaccination programmes (10-12). The allocation of COVID-19 vaccines has 99

been evaluated in combination with NPIs (13-15), with age-varying vaccine efficacy (16), and with 100 different sizes of the vaccine stockpile (17, 18) . These studies examined plausible scenarios with 101 numerous combinations of models and parameters; however, the challenge here is that there are 102

innumerable possible allocation schemes to compare. 103

Here we show a data-driven approach to find optimal allocation schemes, by age group 104

and vaccine type, that minimize either new infections, hospitalizations, or deaths. As per previous 105 studies (13-18), we stratify the population by age, because age is shown to be an important risk 106 factor for susceptibility (19, 20) , severe illness (21,22), and mortality (21, 23, 24) . We apply the 107

proposed approach to a simulated epidemic to evaluate its performance. We also test it with 108 epidemiological data of COVID-19 in the Netherlands, in order to find optimal allocation schemes 109

for different types of vaccines. 110 111

We are interested in prioritizing a subgroup, to target vaccination of individuals in group , 114 by considering within-and between-subgroup transmissions. To find optimal allocation schemes, 115

the proposed approach relies on establishing the impact of a single unit of vaccine (i.e., the number 116 of doses to fully immunize a single individual), as described in the following three steps. 117

First, we write an age-stratified transmission process in matrix form by introducing the 118 next generation matrix (25-27). The next generation matrix gives the number of new infections 119 in a successive generation, such that the number of new infections at time + 1 after one 120 generation of infections is ( + 1) = ( ). Note that is a × matrix, and we have age 121 groups. We start with a × 1 vector of age-specific infection at time , ( ). 122

Second, we define the "impact" of a single unit of vaccination as the reduction in the 123 number of new infections generated by an infected individual. A decrease in the number of 124 infected individuals at time + 1, ( + 1), is expressed as a result of changes in the next 125 generation matrix and in the number of infected individuals ( ) due to vaccinating one 126 individual. With simplified notation, we can write this as ′( + 1) = ′ ( ) + ′( ), where ′ 127

and ′( ) are derivatives with respect to the number of vaccinated individuals; ′ ( ) is the direct 128 effect of vaccinating an individual and removing them from the susceptible population and ′( ) 129

is the indirect effect of vaccinating a single individual by reducing onward infections (see Eq.S4 130

and Eq.S7 for full notation). 131

Third, the main interest here is to approximate the next generation matrix using 132 observed epidemiological data. By approximating , we can calculate above-defined changes 133

without knowing the detailed contact information between groups. To derive the approximated 134

form, we require that at-risk contacts are reciprocal. With this condition, the next generation 135 matrix can be safely approximated by the combination of the force of infection ( ) ( ) (i.e., 136 incidence rate of new infections ( ) per susceptible individual ( )) and the incidence rate of 137 new infections per individual ( ) , and its approximation error is guaranteed to be small if the 138 observation interval for new infections is more than two generation intervals (28) (see detailed 139 derivation in SI Text-1). 140

Using the above results, when age group is targeted for vaccination, its impact can be 141 measured as the contribution of the change in group to the relative reduction in the number of 142 new infections after one generation of infection (see Eq. S11 in SI Text-1). As a result, we can 143 define this quantity as the "importance weight" of infection ( ) , given by 144

where is the reproduction number, and are normalizing constants, ( ) and ( ) are vaccine 146 efficacies for susceptibility and transmissibility in age group , is per contact probability of 147

transmitting infection for age group , and is per contact probability of acquiring infection for 148 age group . We can interpret the quantity ( ) as the expected reduction in the number of new 149

infections generated by an infected individual after introducing a single unit of vaccine in group i, 150 compared with the counterfactual situation where no vaccine is introduced. 151

The importance weight can be generalized for other disease outcomes. We find that the 152 generalized form of Eq.1 for other disease outcomes can be written as the product of the relative 153 change in the number of new infections ( ) and a disease progression rate (see the derivation in SI 154

Text-1). To illustrate its application, we introduce the importance weight of hospitalization ( ) 

and death ( ) , which are defined as the relative reduction in the number of hospitalizations and 156 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. where is the infection hospitalization rate and is the infection mortality rate for age group . 161 162

Given a limited stockpile of vaccines, we assess the expected impacts of a single vaccination 164 on the number of new infections, hospitalization, or deaths, with importance weights (i.e., ( ) , 165 ( ) and ( ) shown in Eq.1-3) . In the case that there are multiple types of vaccines, we can define 166

importance weights by vaccine type. To illustrate the algorithm proposed in this study, we use the 167 example of minimization of hospitalization, letting ( )( ) denote the importance weight of 168 hospitalization (H) for vaccine type in age group . By comparing age and vaccine type specific 169

importance weights, the sequential allocation is performed as described below: 170

Step-1: Decide the objective of infection control (in this example, minimizing hospitalization (H)) 171

Step-2: Calculate importance weights ( )( ) per age-group and vaccine type 172

Step-3: Find a combination of age-group and vaccine type that has the largest importance 173

weight; this provides the selected age group and selected vaccine type. 174

Step-4: Allocate a single unit of the selected vaccine to the selected age-group 175

Step-5: Re-calculate importance weights by decreasing the weights in the targeted age-group, as 176

. Others remain the same. 177

Step-6: Repeat above until the end of vaccine stockpile.

Note that in step-5 all the importance weights of the age group are updated. This is because the 179 allocation of one vaccine type depletes susceptible and infectious individuals in the targeted age 180 group, and thus it affects the expected impacts of other vaccines from next iterations (see detailed 181

derivation in SI Text-1). The pseudo code for this algorithm is provided in Table-S2 .

There are four conditions that should be met; (i) the epidemic grows exponentially over the 183 time interval, (ii) at-risk contacts are reciprocal, (iii) the observation interval for new infections is 184 sufficiently long, and (iv) there is no major change in the age distribution of the risk of infection. 185

With these assumptions, we can reconstruct the (approximated) next generation matrix and 186 calculate the expected impact on each outcome due to vaccination, without detailed information 187 about contacts between groups (28).

We test the performance of the proposed algorithm using a simulated epidemic. strategies yielded by our algorithm perform better than other strategies that we tested in most 196 cases (i.e., random allocation, allocation from young to old groups, allocation from old to young 197 groups, and no vaccination) (Figure-1(D)-(F)). 198 199 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Age distribution of allocated vaccines by prioritization scheme 200

We apply the proposed approach to epidemiological data on COVID-19 in the Netherlands.

Higher efficacious vaccines are allocated first, and then lower efficacious vaccines are distributed 202 later on (Figure 2 and Figure S2 ). Figure 2 shows the detailed breakdown of allocated vaccines by 203 age group and vaccine type in each allocation scheme, and all the schemes start with the highest 204 efficacious vaccine (i.e., Pfizer vaccine). Since high vaccine efficacy results in larger impacts per 205 vaccination (Eq-2), it is natural to prioritize the allocation of higher efficacious vaccines.

Depending on the objective of infection control, the type of vaccines that each age group 207 receives would differ. If a specific age group is significantly contributing to the objective, it is 208 better to distribute higher efficacious vaccines to that group. For example, there is a large 209

contribution of age 21-30 for the number of infections (Figure S1 ), and thus higher efficacious 210

vaccines are distributed to that group if the objective is to minimize the number of infections (top 211 row in Figure 2 ). If we wish to minimize the number of hospitalizations or deaths, those vaccines 212

would be distributed to the elderly (second and third rows in Figure 2 ). 213

The optimal timing of switching from one age group to another also varies by objective.

When we set the objective as the minimization of the number of infections or hospitalizations, the 215 selected allocation orders for these two objectives suggest to distribute vaccines to several age-216 groups in parallel (first and second rows in Figure 2 and Figure S3 ). By contrast, when we set the 217 objective as the minimization of the number of deaths, the allocation scheme generally focused on 218 one age group, from old to young, and did not switch to the next age group until the vaccination of 219 the first age group (i.e., age 60+) is finished (third row in Figure 2 and Figure S3 ). In terms of the 220 order and the switching timing, the selected allocation scheme that minimizes deaths is concordant 221

with the current allocation policy in the Netherlands (29). 222 223

Allocation schemes that are optimized for one objective may not be optimal with respect to 225 another, as illustrated by our simulations. If we choose to minimize the number of infections, that 226 allocation scheme is not efficient for the minimization of deaths (Figure 3 (A) ). In contrast, if we 227 wish to minimize the number of hospitalizations or deaths (Figure 3 (B) and (C)), those strategies 228

are not efficient for minimizing infections. Especially, the difference in the expected reduction is 229 larger at the early phase of allocations; this is because mainly younger age groups are drivers of 230 transmission ( Figure S1 (A)), while younger individuals are not in high-risk groups in terms of 231 hospitalization or death (Figure S1 (F) and (G)).

The proposed algorithm finds the best solution at each allocation step. This results in an 233

optimal solution for small stockpiles, but this local optimal solution is not necessarily optimal for 234 larger stockpiles (so called "greedy algorithm" (30)). To elucidate this property, we simulate an 235 alternative situation, before the approval of the Janssen vaccine, where the breakdown of the stock 236

is Pfizer (40%), AstraZeneca (40%), and Moderna (20%). Figure S4 illustrates that the allocation 237 scheme to minimize infections results in nearly equal reduction of infections at the end of 238 allocations compared to the other two schemes, although it performed best at the beginning phase. 239 240 241

The present study proposes a prioritization algorithm that can find an optimal allocation of 243 vaccines to different age groups, even with a limited amount of data. Our simulation results show 244

how optimal allocation differs depending on the objective. We apply the algorithm to available 245 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10. 1101 /2021 Dutch epidemiological data on COVID-19, and the allocation scheme that minimizes deaths is 246 concordant with the current policy in the Netherlands that allocates vaccines from old to young 247

(29). 248

The proposed method provides first principles to find optimal allocation schemes with 249 limited data, and the output can also be used as a complementary tool to existing computational 250

approaches. Previous studies hinged on dynamic modeling to determine the prioritization of 251 vaccine allocation (13, 16, 17) , and our algorithm can inform a near-optimal distribution of vaccines 252

as input values for those simulations. The proposed method can be used as a cross-check of 253 assumptions in dynamic models, because it does not require the detailed information on contact 254 matrices or non-pharmaceutical interventions. In the COVID-19 pandemic, we have already 255 observed immediate changes of the age distribution of reported cases (20,31), and contact patterns 256 during lockdown are different from usual patterns (32). The strength of our approach is that it 257 relies only on routine surveillance data. 258

Choosing a different objective for COVID-19 control implies choosing a different optimal 259 allocation scheme. In the case of SARS-CoV-2 infection, individuals who are at higher risk of 260 severe illness and who transmit are different (19, 22) . Our results ( Fig-1 and Fig-3 ) illustrated that, 261

if we weigh an objective (e.g., minimization of infections) and choose a strategy, the selected 262 scheme is not necessarily efficient for the other objectives (e.g., minimization of hospitalizations 263

and deaths). In our analysis, the difference in the reduction of each outcome was larger at the 264 earlier phase of vaccinations (Fig-3) , indicating the importance of decision-making in the 265 beginning stage of allocations. While vaccine rollout has progressed rapidly in the first half of 2021 266

in high-income countries, there is large vaccine inequity globally (33). In many low-and middle-267

income countries vaccine rollout is hindered by limited supply. An algorithm, such as the one 268

presented here, can be very useful to prioritize vaccine allocation in those countries where 269 maximum impact on disease outcomes must be achieved by a small supply of vaccines. Besides, 270

the proposed method can be easily generalized for a wider range of objectives, by multiplying a 271 disease progression rate (SI Text-1). The contribution of this study is to provide a solution how to 272 determine the subgroup with the largest contribution to different outcomes, given limited data.

When the proposed algorithm is applied, several assumptions and underlying conditions 274

of input values should be checked. First, confirmed case counts may not reflect the actual infection 275 dynamics in the population, depending on the level of ascertainment (34,35) . Our approach relies 276 on the estimates of group-specific incidence and force of infection, as the best proxy of ongoing 277 transmission, and thus potential biases in the surveillance should be carefully scrutinized. Second, 278

our modelling simplified offering vaccine doses as a single event and parameterized vaccine 279 efficacies as the ability of reducing infections ( ) and blocking transmissions ( ), separately. 280

While there is an advantage to be able to evaluate various characteristics of vaccines by 281

incorporating both the marginal benefit and direct protection, additional supportive evidence on 282 the vaccine efficacy is required. Third, we assume that risk contacts are reciprocal and that 283

individuals are randomly mixing in each group. Although the reciprocity is not violated by a 284 broad class of diseases (32,36), if there were a specific age group that refuses vaccinations, and if its 285

proportion became significantly large, that kind of clustering effect might influence the result of 286 approximation of transmission processes. 287

In conclusion, the present study proposes an approach to find an optimal allocation of 288

vaccines for various objectives, given routine surveillance data. The principle of allocation is 289 simple and interpretable. These features are essential for decision making and for answering to 290 ethical questions that are inherent to allocation of scarce resources. In the context of COVID-19 291 control, the ability to base important decisions on real-time data, rather than the assumed effect of 292 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260889 doi: medRxiv preprint contact patterns and non-pharmaceutical interventions, might provide a more robust scientific 293 basis for COVID-19 control. 294 295 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 vaccination (red), allocation from old to young groups (yellow), young to old groups (purple), at 422 random (blue), and optimized allocation (green). For simplicity, the vaccination coverage was set 423 as 40%, and the effect of vaccines was in place at day 50 (from the initial time point of the 424 simulation), resulting in the immediate depletion of susceptible and infected individuals on that 425 day. 426 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. that the X-axis shows the percentage of allocated vaccines. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

The population data was stratified into six age groups [<20, 21-30, 31-40, 41-50, 51-60, 60+] .

For each age group, we used data on the population size, seroprevalence, incidence of notified 445 cases, maximum vaccine uptake (i.e., willingness to be vaccinated), COVID-19 hospitalization rate, 446

COVID-19 mortality rate, and vaccine efficacy against infection and transmission (Figure S1 ). The 447

seroprevalence data was obtained from the Pienter-Corona study among a representative sample 448 of the Dutch population, collected in June 2020 (37). We used this data to calculate the proportion 449 of susceptible individuals per group, that is, 1 -seropositive rate. We used infection 450 hospitalization rate and infection mortality rate that were estimated by published studies based on 451 pooled analyses over 45 countries (22,24) rather than specific estimates for the Netherlands. 452

The maximum vaccine uptake was assumed to be 80% for all age groups. The vaccine 453 efficacy was assumed constant over age-groups (38-41). We assumed the same vaccine efficacies 454 against infection and transmission (Figure-S1 ). To calculate the expected decrease in the number of 455 new infections, hospitalizations, and deaths, as a function of the number of allocated vaccines, the 456 starting point of effective reproduction number R (i.e., the reference point without any vaccination) 457

was set to 1.2.

We allocated a vaccine stockpile that covers 80% of the total population. The breakdown of 459 the stock is Pfizer (46%), AstraZeneca (22%), Moderna (8%), and Janssen (24%). Note that we 460

considered the unit of vaccines as a set of full doses; for example, the Pfizer vaccine needs to be 461 administered twice, and the set of those two doses was defined as a single unit here. We assumed 462 that one person can receive only one type of vaccines. Thus, 80% of the population was vaccinated 463 when all vaccines were allocated.

Performance evaluation with simulated epidemics 466

We simulated an epidemic, using a deterministic SIR model, where all parameters were 467 known a priori. We evaluated five different allocation strategies: optimal allocation for each 468 objective (i.e., minimization of infections, hospitalizations, and deaths) determined by the 469 proposed algorithm; random allocation; allocation from young to old groups; allocation from old 470 to young groups; and no vaccination. To quantify the impact of vaccinations in each strategy, we 471 took the "no vaccination" scenario as a natural reference point. The population was stratified by 10 472

year age group, since a contact matrix of the Netherlands in June 2020 was available with those age 473 bins and used for the simulation (32). An age-structured SIR model was used to generate an 474 epidemic curve where R0 was set as 1.2 with the fixed generation time as 5 days, based on the 475 estimates of SARS-CoV-2 infections following previous modelling studies (13,16). For simplicity, 476

per contact probability of acquiring infection ( ) and per contact of transmitting infection ( ) were 477 assumed to be equal, and the vaccine efficacy was 0.946 based on the estimate for Pfizer (38). The 478

available vaccine stock was set as 40% coverage of the population, which covers a half of the 479 population that are willing to get vaccinated. 480

As a practical application, observable information (i.e., the incidence of infection and the 481 force of infection) until day 45 was used as inputs, where day 0 is the initial time point of a 482 simulated SIR epidemic. The optimal distribution of vaccines to each age group was yielded by the 483

proposed algorithm. Note that the algorithm does not use the contact matrix. In each scenario, the 484 effect of allocated vaccines became in place at day 50 all at once, resulting in the immediate 485 depletion of susceptible and infected individuals in the population. Replication code is available 486

on GitHub (https://github.com/fmiura/VacAllo_2021). 487 488 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260889 doi: medRxiv preprint

For a broad class of compartmental models, the disease transmission is described as 490

transitions from discrete states (e.g., susceptible-infectious-recovered states in the SIR model), and 491 the dynamics is generated by a system of nonlinear ordinary differential equations (ODEs) that 492 depicts the change over time. By linearizing ODEs, any (linear) system can be described by a 493 matrix form (26). Within this linearized subsystem, one can determine the reproduction number R 494

as the dominant eigenvalue of the next generation matrix (25-27). 495

The first step is to relate the observed data to the next generation matrix . If at-risk 496

contacts are reciprocal, the next generation matrix becomes a product of symmetric matrices and 497

diagonalizable. This condition allows the decomposition of , and thus we can approximate by 498

the top left and right eigenvectors that can be (approximately) described by the incidence of new 499

infections and force of infection (28). 500

Once the matrices are specified, we can evaluate the impact of a single unit of vaccination, 501 as the sensitivity (or elasticity) of the transition matrix (see the general idea of the sensitivity of a 502 matrix in (42), and its application in infectious disease epidemiology in (27,43) ). The change in the 503 number of infections per single vaccination can be formulated as the result of depletion of 504 susceptible and infectious individuals from the population (Eq-S4 in Text-S1), and subsequently, 505

we obtain its effect on the dominant eigenvalue of the next generation matrix that was already 506

introduced in the first step as an approximation with observed data. The expected impact here is 507 defined as the importance weight; if we allocate a single unit of vaccine to the group with the 508 largest importance weight, that results in the minimization of the dominant eigenvalue, that is, the 509 expected number of infections, hospitalizations, or deaths in total. 510 511 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supporting information 512 Figure S1 . Age-specific input data 513 Figure S2 . Simulated vaccine allocations by age and by vaccine type 514 Figure S3 . Simulated prioritization of age-group by allocation scheme 515 Figure S4 . Simulated impact of vaccinations 516 517 Table S1 . Notation and meaning of variables 518 Table S2 . Pseudo code of the allocation algorithm 519 520

Text S1. Mathematical details 521 522 523 Figure S1 . Age-specific input data for the proposed algorithm to obtain optimal allocation 524 schemes. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 533 Figure S2 . Vaccine allocations based on simulated data when the objective is to minimize the 534 number of infections ((A) and (B)), hospitalizations ((C) and (D)), and deaths ((E) and (F)). In left 535 three panels, from lighter to darker blue, bars indicate Pfizer Moderna, Janssen, AstraZeneca. In 536 right three panels, the darker color shows the older age groups, and age bins are [20<,21-30,31-537 40,41-50,51-60,60+] . 538 539 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 540 Figure S3 . Vaccine allocation based on simulated data when the objective is to minimize the 541 number of infections (A), hospitalizations (B), and deaths (C). The darker color shows the older age 542 groups, and age bins are [20<,21-30,31-40,41-50,51-60,60+] . 543 544 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 545 Figure S4 . Performance of allocation schemes on different objectives for a stockpile that suffices to 546 vaccinate 80% of the population. The breakdown of the stock is Pfizer (40%), AstraZeneca (40%), 547

and . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10. 1101 /2021 Update all importance weights of the selected group i that reaches the max uptake: ( )( ) ← 0

Output variables:

• The number of allocated vaccine type j for age group i as a function of iteration : ( ) ( )

• Importance weights per age group i per vaccine type j as a function of iteration : ( )( ) ( ) 559 560 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10. 1101 /2021 Text S1. Mathematical details 561 562

1. Mathematical details 563

1.1 Objective 564

The aim of following calculations is to formulate the expected impact of targeted 565

vaccinations. We firstly present our approach to relate the expected changes in the next generation 566 matrix to the observed epidemiological data (i.e., the number of new infections per group). We 567 then generalize the argument to quantify the expected impact in the number of hospitalizations 568

and deaths. 569

The following analysis is known as "perturbation analysis" of a matrix in demography and 570 population ecology (42,44), and we will refer to theorems and proofs introduced by those exiting 571

literatures. For consistent notations, we follow Magnus and Neudecker (1988) (45); matrices are 572 denoted by upper case bold symbols (e.g., A), and vectors are denoted by lower case bold symbols 573 (n). Note that we define the derivatives of a matrix (or vector) as the matrix (or vector) of 574 derivatives of the elements (e.g., = ( ) and = ( )). All notations and definitions of 575 variables are shown in Table-S2.  576  577 1.2 Next generation matrix 578

The host population is subdivided into m groups. The next generation matrix gives the 579 number of new infections in a successive generation, such that the number of new infections at 580 time + 1 after 1 generations of infections is ( + 1) = ( ). For a large class of transmission 581 models such as susceptible-infected-recovered model (SIR) model, the next generation matrix 582

can be written as 583 = 584

where matrices , , , and have the following epidemiological interpretation: is a matrix with 585 group-specific number of susceptible individuals ( ) on the diagonal, is a matrix with per 586

contact probability of acquiring infection on the diagonal, is a contact matrix with elements 587

, and is a matrix with group-specific per contact probability of transmitting infection on the 588 diagonal. Note that only is time-dependent (and thus is also time-dependent). For readability, 589

when it is obvious from the context, we do not write the dependency on time. We require that at-590 risk contacts are reciprocal, and thus the matrix is assumed to be symmetric. Thus, the next 591 generation matrix becomes a product of symmetric matrices and diagonalizable. 592 593

By diagonalizing the next generation matrix , we have 595 = − 596 where is a diagonal matrix that has eigenvalues , 2 , 2 , ..., as its elements and zeros 597 elsewhere, where is the dominant eigenvalue and is often referred to as the reproduction 598

number. The matrix has as columns the right eigenvectors 1 , 2 ,..., . The matrix − is the 599 inverse of the matrix that has the left eigenvectors 1 , 2 ,..., as its rows. We require that an 600

infector introduced in an arbitrary group reproduces a finite number of new infections in every 601 group, and this condition ensures that the next generation matrix is primitive. In such condition, 602

the Perron-Frobenius Theorem guarantees that , 1 , and 1 are real and non-negative (25,42). 603

After τ generations of infections, the number of new infections at time + is given by ( + 604 ) = ( ) = − ( ). By using both right and left eigenvectors, we can rewrite the formula 605 as 606 ( + ) = ∑ ( ). 607 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Note that ( ) is a vector that has the number of new infections in age group i as its elements, 608 denoted as xi(t) and that the dominant eigenvalue 1 is the reproduction number . If the 609 dominant eigenvalue is strictly greater than other eigenvalues, the first term 1 1 will eventually 610 dominate other terms, and other all the terms will become negligible. This characteristic yields the 611 approximated next generation matrix 612 ̅ = 1 1 .

Now it is of interest to approximate the top right and left eigenvectors, 1 and 1 , by 614

observations. If the observation interval is long enough (typically longer than two generations of 615 infections), we can safely approximate the top right eigenvector 1 with the number of new 616

infections ( ) (28). Thus, we have 617

where is the normalizing constant given by = 1 ∑ ( ) . This result is also known as the strong 619 ergodic theorem (see ref (46), p.86). Since the contact matrix is symmetric and thus the next 620 generation matrix is a product of symmetric matrices, there exists a transformation matrix 621

that transposes , such that − = . With this relationship, we can project the top left 622 eigenvector 1 along the top right eigenvector 1 , and subsequently where is a diagonal matrix that has elements of total population in each age group . Since . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021.

Note that the vaccine efficacy of susceptibility here (i.e., ) 650 is defined as the probability of protecting infection per infectious contact (see next section 1.4.3 for 651 another effect of vaccinations, which considers the prevention of transmission from an infectious 652 individual)

( . 7) 664The interpretation of first term is the reduction in the number of new infections because 665 susceptible individuals were depleted (i.e., direct effect), and that of second term is the effect 666preventing onward infections because infectious individuals are depleted (i.e., indirect effect). 667Now we can relate this sensitivity ( +1) to observations. By approximating the next 668 generation matrix by dominant right and left eigenvectors (i.e., ̅ = 1 1 ), the above equation is ( . 9) 674We use the same approximation method as section 1.3 for the projection matrix ( ) and its top 675 right eigenvector 1 ( ) . Given the sufficient length of observation intervals, we can safely 676 approximate 1 ( ) by the number of new infections ( ) such that 1 ( ) ≈ ( ) (see ref (46), p.86). 677( ) , the contribution of age group i to the dominant eigenvalue 1 ( ) is: 678We can interpret the quantity where is a diagonal matrix with group-specific hospitalization rate 1 , 2 , ...,. Suppose that 691we wish to predict the number of hospitalizations after one generation of infections. We can write 692 the number of new hospitalizations as 693 ( + 1) = ( + 1) = ( ). 694Over the observation interval from to + 1, we assume the group-specific probability of 695 hospitalization is constant. 696Here we look at the perturbation of the expected number of hospitalizations ( + 1) due to 697vaccinations. Since the infection hospitalization rate matrix is constant, the perturbation in ( + 698 1) is of interest. Therefore, using Eq.S4, the decrease in the number of hospitalizations can be 699 written as 700 ( + 1) = ( + 1) = ( ( ) + ( ) ) .( . 12) 701 7021.5.2 Importance weight of hospitalization 703Using Eq.S12 and the result of section 1.4.4 such as Eq.S8, the small change in the expected 704number of hospitalizations after one generation is now written as 705 ( + 1) = ( + 1) = − ( −1Again, we set a projection matrix as ( ) = ( −1 1 1 + 1 1 T −1 ) and its dominant 707 eigenvalue as 1 ( ) . When the vaccination is targeted to the group i, the relative change in the 708 dominant eigenvalue 1 ( ) is 709We define this expected impact of a single vaccination in group i on the dominant eigenvalue 1 ( )

as the importance weight of hospitalization: 712( . 14) 713We can interpret this quantity ( ) as the expected reduction in the number of new 714hospitalizations generated by a typical infected individual in group i after introducing a single unit 715 of vaccine. 716 7171.6 Importance weights for other objectives 718We can replace the matrix (i.e., a diagonal matrix with the elements of infection 719 hospitalization rates per group i) with different rate matrices for other objectives. In this study, we 720 also aimed to test an allocation strategy to minimize the number of deaths. Thus, we introduced a 721 diagonal matrix with group-specific infection mortality rate on the diagonal, and the 722 importance weight of death ( ) can be derived in the same manner as the section 1.5; 723We can interpret this quantity ( ) as the expected reduction in the number of new deaths 725 generated by a typical infected individual in group i after introducing a single unit of vaccine. 726 727 1.7 Changes in importance weights during the allocation of vaccines 728Since importance weights are dependent on the number of allocated vaccines, we need to 729 update them at each allocation step. We denote the changes in importance weights in group i per 730 single allocation as ( ) , ( ) , and ( ) for each objective. 731